Indeed, we found that the higher insoluble p-tau was associated with lower CLDN5 levels, suggesting that aggregation of p-tau or tau pathology may contribute to the impairment of BBB integrity in AD. The gene discussed is MAPT; the disease is Alzheimer disease.